Results from preclinical in vivo studies suggest that Clearmind’s drug candidate MEAI may be effective in treating addiction without disrupting natural reward processes.
TEL AVIV, Israel, January 17, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”) is focused on developing therapeutics to treat disorders. is a professional clinical-stage pharmaceutical company. announced today that Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND) has confirmed additional positive preclinical findings in an ongoing series of research studies on cocaine treatment using his MEAI, a novel psychedelic molecule. announced the results. FSE: CWY).
The results relate to an ongoing collaboration and provisional patent application between the Company and Clearmind to treat cocaine addiction with Clearmind based on palmitoylethanolamide, the active ingredient in SciSparc’s CannAmide™, and Clearmind’s MEAI. doing. A patent application was filed with the US Patent and Trademark Office in June 2022.
The preclinical study was led by Professor Gal Yadid of the Gonda Comprehensive Brain Research Center, Bar-Ilan University, Israel. As previously announced on August 24, 2022, Clearmind’s proprietary HIS MEAI at a dose of 5 mg/kg is effective in treating cocaine addiction by reducing cocaine cravings. There is a possibility.
Our most recent research study was designed to assess the effects of MEAI on natural rewards, as reward-based positive reinforcement is an evolutionary survival strategy shared across species. However, in drug addiction, reward-seeking becomes maladaptive, endangering survival. The aim of this in vivo study was to conclude whether MEAI uses the same underlying mechanisms to seek both drug and natural rewards (such as sucrose). Results show that natural reward is maintained in his MEAI-treated rats, thus indicating that the effect of her MEAI on drug-seeking is not related to the general reward system. .
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialist clinical-stage pharmaceutical company led by an experienced team of senior management and scientists. SciSparc’s focus is to create and enhance a portfolio of cannabinoid pharmaceutical-based technologies and assets. With this focus, we are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD. SCI-160 for the treatment of pain; SCI-210 for the treatment of ASD and status epilepticus.
About Clearmind Medicine
Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve a wide range of underserved health problems, including alcohol use disorders. I guess. Its primary purpose is to research and develop psychedelic-based compounds and commercialize them as regulated drugs, foods, or supplements.
The company’s intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted, and remains opportunistic in acquiring additional intellectual property to build its portfolio.
Clearmind shares are listed on the Nasdaq and Canadian Stock Exchanges under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, SciSparc uses forward-looking statements in discussing Clearmind’s intention to seek additional patents on its compounds and Clearmind’s opportunistic nature to acquire additional intellectual property. increase. Past results of scientific studies and clinical and preclinical trials are no guarantee that the conclusions of future studies or trials will suggest the same or similar conclusions. Such statements deal with future events and are based on SciSparc’s current expectations and are subject to various risks and uncertainties, and SciSparc’s actual results, performance or achievements may not be accurate in this press release. It may differ materially from what is stated or implied in the description. The forward-looking statements contained in or implied in this press release are made in SciSparc’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 under the heading “Risk Factors.” are subject to other risks and uncertainties, including those discussed in It was later filed with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc makes forward-looking statements only as of the date they are made, whether as a result of new information, future events, circumstances or otherwise. disclaims any intention or obligation to update or revise any statements relating to